Illustration: Shutterstock
July 19, 2023 11:14 AM EDT
Financing
Startups
Deals

Biotech’s op­ti­mism is re­turn­ing amid signs of a bet­ter sec­ond half and a brighter 2024

Kyle LaHucik

Senior Reporter

Odysseus even­tu­al­ly made it to shore, as Bridge­Bio CEO Neil Ku­mar re­mind­ed the in­dus­try last Fri­day in a nod to Homer’s clas­sic tale. And …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times